St. Jude Medical has launched the Axium Neurostimulator System for dorsal root ganglion stimulation in the United States.
Here are five highlights:
1. The Axium Neurostimulator System for DRG stimulation is used to treat patients with chronic pain that has been hard to control with traditional spinal cord stimulation.
2. First commercial implants of the device occurred at the Center for Pain Relief in Charleston, W.Va., by Timothy R. Deer, MD, and at the Sutter Santa Rosa Surgery and Endoscopy Center in Santa Rosa, Calif., by Jason E. Pope, MD.
3. Over the course of the year, the company expects to have more than 300 physicians across the country trained to effectively deliver DRG therapy to patients in immediate need of targeted stimulation to alleviate chronic pain resulting from moderate to severe chronic intractable pain of the lower limbs in adult patients with complex regional pain syndrome types I and II.
4. Approval of DRG stimulation with the St. Jude Medical Axium Neurostimulator System was based in part on the results of the ACCURATE IDE study, which evaluated patients suffering from neuropathic chronic intractable pain associated with CRPS I and II or peripheral causalgia and found DRG stimulation provided patients with superior pain relief over traditional tonic spinal cord stimulation.
5. St. Jude Medical is a medical device company headquartered in St. Paul, Minn., focused in the areas of heart failure, arrhythmias, vascular disease, structural heart, chronic pain and neurological diseases.